Imagine a tiny pump, way smaller than current ones, that delivers medicine through the skin. It uses special ceramic materials that act like a microscopic muscle to push fluid forward. This allows for a patch that is nearly invisible and uses very little battery power.
Current insulin pumps are too bulky, consume too much energy, and lack the precision required for complex multi-hormone treatments, limiting patient adoption.
A thin-film micropump using ceria-based oxide actuators. Deliverables include a numerical model for geometry and a rotational support for PVD manufacturing.
If you are a device manufacturer dealing with bulky wearable pumps — this project developed a thin-film micropump that is more than two orders of magnitude smaller than state of the art. This allows for a much less intrusive patch for diabetic patients.
If you are a developer dealing with the complexity of delivering multiple hormones simultaneously — this project developed a modular pump system. This enables the realization of multi-drug delivery systems for more complex treatments.
If you are a startup dealing with high battery drain in wearables — this project developed a pump with a drastic reduction in energy consumption. This extends the life of the wearable device for the end user.
Based on available project data, specific unit costs or pricing models are not provided; the focus is on validating the manufacturing process.
The project's main objective is to validate the manufacturing process in a real operating environment to prove specifications are consistently met for system integrators.
The project aims to pave the way for the launch of a startup company that will establish long-term cooperation agreements with medical device manufacturers.
The pump is designed as a thin-film component to be integrated into wearable insulin patch pumps and multi-hormone smart patches.
The project runs from 2022-07-01 to 2025-06-30, with post-project steps including system integration and clinical validation.
The consortium consists of 4 partners across 4 countries (DK, ES, IL, IT). It is heavily research-oriented with 3 universities and only 1 SME (25% industry ratio), indicating that while the technology is grounded in academic excellence (led by DTU), it is currently in the transition phase toward commercialization via a planned startup.
Contact the Technical University of Denmark (DTU) regarding the PRISMA project.
Contact us to facilitate a partnership with the PRISMA consortium for clinical validation.
